Observational studyInfluenza and other respiratory viruses2026
Longitudinal SARS-CoV-2 Antibody Response in Healthcare Workers: Benefit of Prior Infection and Heterologous Boosting on Anti-Spike IgG Immunity.
Observational study in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Longitudinal SARS-CoV-2 Antibody Response in Healthcare Workers: Benefit of Prior Infection and Heterologous Boosting on Anti-Spike IgG Immunity.Influenza and other respiratory viruses · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectivesDifferent COVID-19 vaccine platforms elicit variable immune responses, influenced by prior infection and booster vaccination. We aimed to compare the humoral immune responses elicited by mRNA and adenoviral vector (Ad-vector) COVID-19 vaccines in hospital employees and to assess the possible impact of prior SARS-CoV-2 infection on these responses.
methodsWe performed a prospective observational cohort study by recruiting employees of the Universitair Ziekenhuis Brussel who were vaccinated with an mRNA or Ad-vector vaccine. We assessed anti-spike (S) IgG and neutralising capacity at 1, 6 and 12 months (post-mRNA booster). Anti-S and anti-NCP IgG were measured by chemiluminescent microparticle immunoassay, and neutralising capacity was assessed using Genscript's cPASS. Non-parametric group comparisons used the Mann-Whitney U test, complemented by multiple linear regression.
resultsFollowing RVR, mRNA-vaccinated individuals (n = 380) exhibited higher anti-S IgG titres and neutralising capacity compared to those who received Ad-vector vaccines (n = 200). After the booster, anti-spike IgG remained higher in mRNA-vaccinated individuals than in Ad-vector recipients (q < 0.001); Ad-vector vaccinated individuals showed superior neutralising capacity. Natural SARS-CoV-2 infection prior to vaccination had varying impact on anti-S IgG and neutralising capacity, depending on vaccination type and time points.
conclusionOur findings underscore that both vaccine platforms and prior infections shape the magnitude and quality of the humoral immune response, highlighting the importance of considering priming strategy, booster design and hybrid immunity when optimising COVID-19 vaccination schedules for durable protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.